This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
by Mark Vickery
Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses
by Mark Vickery
Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
by Zacks Equity Research
Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
Exploring Analyst Estimates for Gilead (GILD) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Gilead Sciences (GILD) reachead $79.07 at the closing of the latest trading day, reflecting a -0.57% change compared to its last close.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
by Zacks Equity Research
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
by Zacks Equity Research
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
Company News for Jan 23, 2024
by Zacks Equity Research
Companies In The Article Are:GILD,ADM,NS,SUN,RUM
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
by Ekta Bagri
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $81.01, marking a -0.16% move from the previous day.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
Gilead Sciences (GILD) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $78.59, denoting a -1.13% change from the preceding trading day.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $81.78, denoting a -1.58% change from the preceding trading day.